Uniplan Investment Counsel’s Aurinia Pharmaceuticals AUPH Stock Holding History

Uniplan Investment Counsel’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.22M	Buy	189,542 +74,941	+65%	+$1.2M	0.3%	89
2026 Q1	$1.7M	Sell	114,601 -11,015	-9%	-$161K	0.17%	113
2025 Q4	$2M	Buy	125,616 +34,059	+37%	+$483K	0.2%	116
2025 Q3	$1.01M	Buy	+91,557	New	+$1M	0.1%	146

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Uniplan Investment Counsel's AUPH Position: Q2 2026 in Review

Uniplan Investment Counsel increased its Aurinia Pharmaceuticals (AUPH) stake by 65% in Q2 2026, buying an estimated $1.2M and bringing the position to 189,542 shares worth $3.22M. The position accounts for 0.3% of the portfolio, ranked #89.

Uniplan Investment Counsel first reported a position in AUPH in Q3 2025 and has held it in 4 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Uniplan Investment Counsel held 189,542 shares of Aurinia Pharmaceuticals worth $3.22M as of Q2 2026.
Uniplan Investment Counsel bought 74,941 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $1.2M.
Aurinia Pharmaceuticals made up 0.3% of Uniplan Investment Counsel's portfolio in Q2 2026, its #89 holding.
Uniplan Investment Counsel first reported a position in Aurinia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Uniplan Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.